Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer

NCT00003557 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT00003557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
January 31, 1999
Completion date
August 31, 2003
Enrollment
16 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

extrahepatic bile duct cancer, gallbladder cancer, liver cancer